INTENSITY THERAPEUTICS
Intensity Therapeutics, Inc., a biopharmaceutical company, provides chemotherapy treatments for cancer patients. It engages in the direct intratumoral injection of novel pharmaceutical formulations for cancer administration. Intensity Therapeutics, Inc. was incorporated in 2012 and is based in Norwalk, Connecticut.
INTENSITY THERAPEUTICS
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2012-01-01
Address:
Norwalk, Connecticut, United States
Country:
United States
Website Url:
http://www.intensitytherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
2036641051
Email Addresses:
[email protected]
Total Funding:
11.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Current Employees Featured
Founder
Investors List
Jim Mellon
Jim Mellon investment in Series A - Intensity Therapeutics
SalvaRx Group PLC
SalvaRx Group PLC investment in Series A - Intensity Therapeutics
VCapital
VCapital investment in Series A - Intensity Therapeutics
Batterson Venture Capital
Batterson Venture Capital investment in Series A - Intensity Therapeutics
Declan Doogan
Declan Doogan investment in Series A - Intensity Therapeutics
Official Site Inspections
http://www.intensitytherapeutics.com
- Host name: 157.53.209.35.bc.googleusercontent.com
- IP address: 35.209.53.157
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Intensity Therapeutics"
Company - Intensity Therapeutics
Intensity Therapeutics is a clinical-stage biotechnology company whose mission is to help patients live longer, higher quality lives by discovering, developing, and commercializing first-in-class …See details»
Intensity Therapeutics, Inc. (INTS)
Nov 13, 2024 Intensity Therapeutics, Inc. is a late-stage clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anticancer immune …See details»
Company Information - Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a late-stage clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anticancer immune activation. Our new approach …See details»
Board of Directors - Intensity Therapeutics
Prior to her appointment as CEO of PsychoGenics, she was Vice President of Business Development, a position she also held at American Biogenetic Sciences and at AMBI Inc. Dr. …See details»
Intensity Therapeutics - Crunchbase Company Profile & Funding
Intensity Therapeutics is a biopharmaceutical company that provides chemotherapy treatment for cancer patients.See details»
Intensity Therapeutics, Inc. (INTS) - Yahoo Finance
See the company profile for Intensity Therapeutics, Inc. (INTS) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Intensity Therapeutics, Inc. | LinkedIn
Intensity Therapeutics, Inc. Pharmaceutical Manufacturing Westport, CT 974 followers A clinical stage biotechnology company whose mission is to create safer and more efficacious cancer therapies.See details»
News & Events - Intensity Therapeutics, Inc.
WESTPORT, Conn., July 10, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery …See details»
Intensity Therapeutics - PitchBook
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology …See details»
Senior Management Team - Intensity Therapeutics
Joseph Talamo has over 25 years of biopharmaceutical company experience in financial leadership roles, and has served as our Chief Financial Officer since December 2023. Prior to joining Intensity Therapeutics, Mr. Talamo served as …See details»
Intensity Therapeutics, Inc. (INTS) - Yahoo Finance
Find the latest Intensity Therapeutics, Inc. (INTS) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Intensity Therapeutics Reports Third Quarter Financial Results and ...
Nov 13, 2023 For more information about the Company, including publications, papers and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com. …See details»
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in …
Nov 18, 2024 Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of …See details»
Clinical Research - Intensity Therapeutics
Disease progression will be determined by the World Health Organization (WHO) Criteria. Participants will be prospectively stratified into 1 of 3 histologically defined aSTS strata: • …See details»
Intensity Therapeutics Provides Business Update Reflecting …
Jan 3, 2024 For more information about the Company, including publications, papers and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com. …See details»
News - Intensity Therapeutics
May 15, 2024 Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) MeetingSee details»
Intensity Therapeutics Reports First Quarter 2024 Financial Results …
SHELTON, Conn., May 9, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the …See details»
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief …
SHELTON, Conn., Dec. 12, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of …See details»
Pipeline - Intensity Therapeutics
Orphan Drug ( Sarcoma INT230-6 components) Tax credits for qualified clinical trials Exemption from user fees Potentially seven years of marketing exclusivity (post approval) Fast Track …See details»